Skip to content
Triangle logo TriangleGet started
← Full study record

NCT03132922 · OUTCOME

Best Overall Response (BOR)

MAGE-A4ᶜ¹º³²T for Multi-Tumor · Source last updated 2026-06-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
From afamitresgene autoleucel infusion until disease progression/recurrence (up to 3.2 years)

What was measured

BOR was defined as the best response recorded from the date of T-cell infusion until disease progression. Response categories from best to worst were, confirmed CR, confirmed PR, stable disease (SD), progressive disease (PD), and not evaluable (NE) (per RECIST v1.1)

Analysis population: Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel

Groups in this outcome

Afamitresgene Autoleucel, Group 1

Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells

Afamitresgene Autoleucel, Group 2

Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells

Afamitresgene Autoleucel, Group 3 + Expansion

Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells

Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel

Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Afamitresgene Autoleucel, Group 13
Afamitresgene Autoleucel, Group 23
Afamitresgene Autoleucel, Group 3 + Expansion32
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel4

Reported measurements

Complete response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 10Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 20Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 3 + Expansion0Not reportedNot reportedNot reportedNot reported
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel0Not reportedNot reportedNot reportedNot reported
Partial response
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 10Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 20Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 3 + Expansion9Not reportedNot reportedNot reportedNot reported
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel1Not reportedNot reportedNot reportedNot reported
Stable disease
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 12Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 23Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 3 + Expansion14Not reportedNot reportedNot reportedNot reported
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel3Not reportedNot reportedNot reportedNot reported
Progressive disease (PD)
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 11Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 20Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 3 + Expansion6Not reportedNot reportedNot reportedNot reported
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel0Not reportedNot reportedNot reportedNot reported
Not evaluable
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Afamitresgene Autoleucel, Group 10Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 20Not reportedNot reportedNot reportedNot reported
Afamitresgene Autoleucel, Group 3 + Expansion3Not reportedNot reportedNot reportedNot reported
Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel0Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        0
      4. group Id
        OG003
        value
        0
    title
    Complete response
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        9
      4. group Id
        OG003
        value
        1
    title
    Partial response
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        2
      2. group Id
        OG001
        value
        3
      3. group Id
        OG002
        value
        14
      4. group Id
        OG003
        value
        3
    title
    Stable disease
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        1
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        6
      4. group Id
        OG003
        value
        0
    title
    Progressive disease (PD)
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        0
      3. group Id
        OG002
        value
        3
      4. group Id
        OG003
        value
        0
    title
    Not evaluable
denoms
  1. counts
    1. group Id
      OG000
      value
      3
    2. group Id
      OG001
      value
      3
    3. group Id
      OG002
      value
      32
    4. group Id
      OG003
      value
      4
    units
    Participants
description
BOR was defined as the best response recorded from the date of T-cell infusion until disease progression. Response categories from best to worst were, confirmed CR, confirmed PR, stable disease (SD), progressive disease (PD), and not evaluable (NE) (per RECIST v1.1)
groups
  1. description
    Participants who received afamitresgene autoleucel 0.1x10\^9 transduced cells
    id
    OG000
    title
    Afamitresgene Autoleucel, Group 1
  2. description
    Participants who received afamitresgene autoleucel 0.5-1.2x10\^9 transduced cells
    id
    OG001
    title
    Afamitresgene Autoleucel, Group 2
  3. description
    Participants who received afamitresgene autoleucel 1.2-10x10\^9 transduced cells
    id
    OG002
    title
    Afamitresgene Autoleucel, Group 3 + Expansion
  4. description
    Participants who received LDR in combination with lymphodepletion chemotherapy followed by the afamitresgene autoleucel infusion.
    id
    OG003
    title
    Low Dose Radiation (LDR) in Combination With Afamitresgene Autoleucel
param Type
COUNT_OF_PARTICIPANTS
population Description
Participants who received afamitresgene autoleucel or LDR/ afamitresgene autoleucel
reporting Status
POSTED
time Frame
From afamitresgene autoleucel infusion until disease progression/recurrence (up to 3.2 years)
title
Best Overall Response (BOR)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice